Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-CCNE1 Recombinant Antibody (CBFYC-1046) (CBMAB-C1103-FY)


See all CCNE1 antibodies
Online Inquiry
Published Data
CBMAB-C1103-FY-1
Mouse Anti-CCNE1 Recombinant Antibody (CBFYC-1046) (CBMAB-C1103-FY) in WB
Western blot analysis of the G1/S transit-related genes in HUVECs treated with or without 1,6-HD. GAPDH was used as the loading control. ...View More
Jiang, Y., Lei, G., Lin, T., Zhou, N., Wu, J., Wang, Z., ... & Mao, R. (2023). 1, 6-Hexanediol regulates angiogenesis via suppression of cyclin A1-mediated endothelial function. BMC biology, 21(1), 75.
CBMAB-C1103-FY-2
Mouse Anti-CCNE1 Recombinant Antibody (CBFYC-1046) (CBMAB-C1103-FY) in WB
Western blot was used to detect the indicated gene expression in GC cells transfected with negative control siRNA or USP13 siRNAs (siUSP13). Cyclin D1 protein was detected using western blot in GC cells transfected with USP13 siRNAs. ...View More
Ma, C., Wang, D., Tian, Z., Gao, W., Zang, Y., Qian, L., ... & Liu, Z. (2023). USP13 deubiquitinates and stabilizes cyclin D1 to promote gastric cancer cell cycle progression and cell proliferation. Oncogene, 42(29), 2249-2262.
CBMAB-C1103-FY-3
Mouse Anti-CCNE1 Recombinant Antibody (CBFYC-1046) (CBMAB-C1103-FY) in WB
The alterations in markers of apoptosis (cleaved-PARP, cleaved-caspase-3) and cell cycle (cyclin D1, E, B1, p53, p21) cause by PLM-101 treatment. PLM-101 was treated for 24 h at the indicated concentration. ...View More
Choi, Y. J., Park, J., Choi, H., Oh, S. J., Park, J. H., Park, M., ... & Kang, K. W. (2023). PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia. Biomedicine & Pharmacotherapy, 165, 115066.
CBMAB-C1103-FY-4
Mouse Anti-CCNE1 Recombinant Antibody (CBFYC-1046) (CBMAB-C1103-FY) in WB
Cells treated only with T were considered the control group. Representative Western blot analysis of cyclin E, cleaved PARP, and pro-caspase-7. β-Actin or total PARP was used as a loading control. The protein expression obtained for treated cells was normalized in relation to the protein expression of the control. ...View More
Bezerra, P. H., Amaral, C., Almeida, C. F., Correia-da-Silva, G., Torqueti, M. R., & Teixeira, N. (2023). In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment. Molecules, 28(13), 4893.
CBMAB-C1103-FY-5
Mouse Anti-CCNE1 Recombinant Antibody (CBFYC-1046) (CBMAB-C1103-FY) in WB
Western blot showing the expression of cell-cycle-related proteins in GDF15-knockdown cells treated with IL-6. ...View More
Joo, M., Kim, D., Lee, M. W., Lee, H. J., & Kim, J. M. (2023). GDF15 promotes cell growth, migration, and invasion in gastric cancer by inducing STAT3 activation. International Journal of Molecular Sciences, 24(3), 2925.
CBMAB-C1103-FY-6
Mouse Anti-CCNE1 Recombinant Antibody (CBFYC-1046) (CBMAB-C1103-FY) in WB
Whole cell extracts from U2OS or transduced U2OS::HA FBXW7 or U2OS::HA FBXW7ΔF cells were electroblotted and probed with the indicated antibodies. Western blot against cyclin E was used as a control of the efficiency of FBXW7 or FBXW7ΔF expression. ...View More
Belmonte-Fernández, A., Herrero-Ruíz, J., Galindo-Moreno, M., Limón-Mortés, M. C., Mora-Santos, M., Sáez, C., ... & Romero, F. (2023). Cisplatin-induced cell death increases the degradation of the MRE11-RAD50-NBS1 complex through the autophagy/lysosomal pathway. Cell Death & Differentiation, 30(2), 488-499.
CBMAB-C1103-FY-7
Mouse Anti-CCNE1 Recombinant Antibody (CBFYC-1046) (CBMAB-C1103-FY) in WB
Protein levels of C/EBPα, p-AKT (ser473), p-AKT (thr308), p-GSK-3β, p-c-Raf, p27, p-p27 (s10), Cyclin E, CDK2 and PCNA were detected by WB. ...View More
Yu, Z., Li, Y., Shao, S., Guo, B., Zhang, M., Zheng, L., ... & Han, T. (2022). Protective effect of hepatocyte-enriched lncRNA-Mir122hg by promoting hepatocyte proliferation in acute liver injury. Experimental & Molecular Medicine, 54(11), 2022-2035.

Summary

Host Animal
Mouse
Specificity
Human, Mouse, Rat
Clone
CBFYC-1046
Antibody Isotype
IgG2b, κ
Application
ELISA, IF, IP, WB, IHC-P

Basic Information

Immunogen
Amino acids 367-396 at the C-terminus of cyclin E of rat origin.
Host Species
Mouse
Specificity
Human, Mouse, Rat
Antibody Isotype
IgG2b, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.
ApplicationNote
WB1:100-1:1,000
IP1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
ELISA1:100-1:1,000
IF(ICC)1:50-1:500
IHC-P1:50-1:500

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, 0.1% gelatin
Preservative
< 0.1% sodium azide
Concentration
0.2 mg/ml
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at-20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Cyclin E1
Introduction
Cyclin E1 (CCNE1) gene amplification has been reported to occur independently of BRCA1/2 mutation, and it is associated with primary treatment failure and reduced patient survival.
Entrez Gene ID
898
UniProt ID
P24864
Alternative Names
Cyclin E1; CCNE; G1/S-Specific Cyclin-E1; Cyclin Es; Cyclin Et; PCCNE1
Function
Essential for the control of the cell cycle at the G1/S (start) transition.
Biological Process
Cell division Source: UniProtKB-KW
DNA replication initiation Source: Ensembl
G1/S transition of mitotic cell cycle Source: BHF-UCL
Homologous chromosome pairing at meiosis Source: Ensembl
Mitotic cell cycle phase transition Source: GO_Central
Negative regulation of transcription by RNA polymerase II Source: Ensembl
Positive regulation of mesenchymal stem cell proliferation Source: BHF-UCL
Protein phosphorylation Source: MGI
Regulation of cellular protein localization Source: Ensembl
Regulation of cyclin-dependent protein serine/threonine kinase activity Source: GO_Central
Regulation of transcription involved in G1/S transition of mitotic cell cycle Source: Reactome
Telomere maintenance Source: Ensembl
Wnt signaling pathway Source: Ensembl
Cellular Location
Nucleus
PTM
Phosphorylation of both Thr-395 by GSK3 and Ser-399 by CDK2 creates a high affinity degron recognized by FBXW7, and accelerates degradation via the ubiquitin proteasome pathway. Phosphorylation at Thr-77 creates a low affinity degron also recognized by FBXW7.
Ubiquitinated by UHRF2; appears to occur independently of phosphorylation.
More Infomation

Sonntag, R., Penners, C., Kohlhepp, M., Haas, U., Lambertz, D., Kroh, A., ... & Liedtke, C. (2021). Cyclin E1 in Murine and Human Liver Cancer: A Promising Target for Therapeutic Intervention during Tumour Progression. Cancers, 13(22), 5680.

Pascual, J., Gil-Gil, M., Zielinski, C., Hills, M., Ruiz-Borrego, M., Ciruelos, E. M., ... & Martin, M. (2021). CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study.

Zhu, W., Si, Y., Xu, J., Lin, Y., Wang, J. Z., Cao, M., ... & Wei, J. F. (2020). Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A‐dependent manner. Journal of cellular and molecular medicine, 24(6), 3521-3533.

Turner, N. C., Liu, Y., Zhu, Z., Loi, S., Colleoni, M., Loibl, S., ... & Cristofanilli, M. (2019). Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor–positive metastatic breast cancer. Journal of Clinical Oncology, 37(14), 1169.

Turner, N. C., Liu, Y., Zhu, Z., Loi, S., Colleoni, M., Loibl, S., ... & Cristofanilli, M. (2018). Abstract CT039: Cyclin E1 (CCNE1) expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial.

Sonntag, R., Giebeler, N., Nevzorova, Y. A., Bangen, J. M., Fahrenkamp, D., Lambertz, D., ... & Liedtke, C. (2018). Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 115(37), 9282-9287.

Huang, X., & Lyu, J. (2018). Tumor suppressor function of miR‑483‑3p on breast cancer via targeting of the cyclin E1 gene. Experimental and therapeutic medicine, 16(3), 2615-2620.

Ehedego, H., Mohs, A., Jansen, B., Hiththetiya, K., Sicinski, P., Liedtke, C., & Trautwein, C. (2018). Loss of Cyclin E1 attenuates hepatitis and hepatocarcinogenesis in a mouse model of chronic liver injury. Oncogene, 37(25), 3329-3339.

Guarducci, C., Bonechi, M., Benelli, M., Biagioni, C., Boccalini, G., Romagnoli, D., ... & Migliaccio, I. (2018). Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer, 4(1), 1-10.

Bangen, J. M., Hammerich, L., Sonntag, R., Baues, M., Haas, U., Lambertz, D., ... & Liedtke, C. (2017). Targeting CCl4‐induced liver fibrosis by RNA interference–mediated inhibition of cyclin E1 in mice. Hepatology, 66(4), 1242-1257.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CCNE1 Recombinant Antibody (CBFYC-1046)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry